Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

39.64 +1.01 (+2.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 439,101
Open 38.64
Bid (Size) 30.95 (100)
Ask (Size) 40.00 (100)
Prev. Close 38.63
Today's Range 37.50 - 40.82
52wk Range 15.93 - 43.66
Shares Outstanding 42,425,071
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire

Performance

YTD
+96.6%
+96.6%
1 Month
+14.5%
+14.5%
3 Month
+46.3%
+46.3%
6 Month
+114.4%
+114.4%
1 Year
+98.4%
+98.4%

More News

Read More
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Inc. Announces Pricing of $125 Million Public Offering
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Inc. Announces Proposed Public Offering
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
Via Stocktwits
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Neurogene Inc.
Via Business Wire

Frequently Asked Questions

Is Neurogene Inc. - Common Stock publicly traded?
Yes, Neurogene Inc. - Common Stock is publicly traded.
What exchange does Neurogene Inc. - Common Stock trade on?
Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurogene Inc. - Common Stock?
The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
What is the current price of Neurogene Inc. - Common Stock?
The current price of Neurogene Inc. - Common Stock is 39.64
When was Neurogene Inc. - Common Stock last traded?
The last trade of Neurogene Inc. - Common Stock was at 08/24/26 04:00 PM ET
What is the market capitalization of Neurogene Inc. - Common Stock?
The market capitalization of Neurogene Inc. - Common Stock is 1.68B
How many shares of Neurogene Inc. - Common Stock are outstanding?
Neurogene Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.